Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4898MR)

This product GTTS-WQ4898MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4898MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6386MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ7514MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ12463MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ4779MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ7931MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ1013MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ1885MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ9173MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW